Table 1.
Characteristics of the B6D2F1 mice in the main cohort (C1.X to C16.X)
| Treatment (iron/ICT) | 0/0 | 7.5/0 | 7.5/10 | 7.5/40 | 15/0 | 30/0 | 30/10 | 30/40 |
|---|---|---|---|---|---|---|---|---|
| C1.XC2.X | C3.XC4.X | C9.XC10.X | C11.XC12.X | C5.XC6.X | C7.XC8.X | C13.XC14.X | C15.XC16.X | |
| N | 13 | 13 | 10 | 10 | 10 | 10 | 10 | 10 |
| Total iron burden (mg) | 0 | 7.5 | 7.5 | 7.5 | 15 | 30 | 30 | 30 |
| Deferasirox (mg/kg/d) | 0 | 0 | 10 | 40 | 0 | 0 | 10 | 40 |
| Mean initial body weight (g) | 27.12 ± 1.57 | 28.21 ± 2.1 | 32.93 ± 2.85 | 30.51 ± 1.79 | 27.68 ± 3.32 | 27.32 ± 1.78 | 31.19 ± 1.48 | 31.69 ± 3.11 |
| Mean maximum body weight (g) | 52.35 ± 3.37 | 50.48 ± 7.05 | 56.37 ± 4.64 | 50.38 ± 4.13 | 52.56 ± 6.05 | 55.91 ± 10.89* | 51.95 ± 5.27 | 56.73 ± 7.52 |
| Mortality due to AML | 0 (0%) | 5 (38%) | 1 (10%) | 3 (30%) | 2 (20%) | 1 (10%) | 3 (30%) | 0 (0%) |
| Total mortality | 2 (15%) | 7 (54%) | 3 (30%) | 4 (40%) | 3 (30%) | 3 (30%) | 3 (30%) | 4 (40%) |
* F-test compared to control P < 0.0005